Učitavanje...
Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
INTRODUCTION: The treatment of lung cancer is not defined in the third-line setting and remains an unanswered question. Erlotinib is the only drug approved in the third-line setting. With the introduction of effective first- and second-line therapies, more and more patients warrant an effective thir...
Spremljeno u:
| Izdano u: | South Asian J Cancer |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wolters Kluwer - Medknow
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6956591/ https://ncbi.nlm.nih.gov/pubmed/31956622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/sajc.sajc_28_19 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|